Ionis Pharmaceuticals, Inc. (IONS)
After hours:
| Previous close | 41.84 |
| Open | 41.75 |
| Bid | 41.55 x 300 |
| Ask | 41.62 x 300 |
| Day's range | 41.36 - 42.28 |
| 52-week range | 34.32 - 54.44 |
| Volume | |
| Avg. volume | 1,077,988 |
| Market cap | 6.062B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.56 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 55.95 |
PR NewswireIonis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders. In 2023, Ionis extended its commitment to corporate responsibility (CR) through the establishment of three strategic pillars with actionable goals. Ionis also committed to continuing to transparently communicate the Company's pr
- PR Newswire
Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
- PR Newswire
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprote
